Analysis of the latest price and purchase cost of eflornithine (IWILFIN) in China

Eflornithine tablets (IWILFIN) is an oral targeted drug mainly used to treat patients with relapsed or refractory glioma carrying IDH1/IDH2 mutations. It inhibits tumor growth by inhibiting the activity of mutant isocitrate dehydrogenase (IDH) and reducing the accumulation of 2-hydroxyglutarate (2-HG). Due to its targeting properties and relatively novel mechanism of action, eflornithine is considered an important drug overseas for the first- or second-line treatment of IDHmutated gliomas.

At present, eflornithine tablets have not yet been officially launched in China, so domestic patients cannot purchase them directly in hospital pharmacies, nor can they enjoy the medical insurance reimbursement policy. This means that if patients want to use the drug, it must be imported through overseas channels, usually involving cross-border medical or clinical trial projects. There are no generic drugs of eflornithine tablets in the domestic market, further limiting patient access.

In overseas markets, the specifications of the original eflornithine drug are192mg*100 tablets. Each box is priced at more than 10,000 US dollars, which is expensive. The high price is mainly due to drug research and development costs, patent protection and clinical application value. This imposes high financial burden on patients and limits the widespread use of drugs worldwide. Patients must fully evaluate their financial affordability when considering use and formulate a reasonable treatment plan under the guidance of a professional doctor.

Overall, eflornithine tablets are not yet popular in the domestic market, and price information and medical insurance policies are still unclear. Its high overseas price and lack of generic drugs make it more expensive for domestic patients to acquire. When patients choose to use this drug, they should scientifically plan treatment plans through formal medical channels and guidance from professional doctors, combined with clinical needs and economic conditions, to ensure safe and effective use of the drug. At the same time, they should avoid purchasing drugs through informal channels to prevent them from affecting efficacy and medication safety.

Reference link:https://www.drugs.com